Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption.

Allard SD, De Keersmaecker B, de Goede AL, Verschuren EJ, Koetsveld J, Reedijk ML, Wylock C, De Bel AV, Vandeloo J, Pistoor F, Heirman C, Beyer WE, Eilers PH, Corthals J, Padmos I, Thielemans K, Osterhaus AD, Lacor P, van der Ende ME, Aerts JL, van Baalen CA, Gruters RA.

Clin Immunol. 2012 Mar;142(3):252-68. doi: 10.1016/j.clim.2011.10.010. Epub 2011 Nov 16.

PMID:
22177848
2.

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.

Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, De Haes W, Wong J, Florence E, Vanham G, Berneman ZN.

AIDS. 2012 Feb 20;26(4):F1-12. doi: 10.1097/QAD.0b013e32834f33e8.

PMID:
22156965
3.

HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption.

de Goede AL, van Deutekom HW, Vrancken B, Schutten M, Allard SD, van Baalen CA, Osterhaus AD, Thielemans K, Aerts JL, Keşmir C, Lemey P, Gruters RA.

AIDS. 2013 Nov 13;27(17):2679-89. doi: 10.1097/01.aids.0000433813.67662.92.

PMID:
24149085
4.

Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes.

Hinkula J, Svanholm C, Schwartz S, Lundholm P, Brytting M, Engström G, Benthin R, Glaser H, Sutter G, Kohleisen B, Erfle V, Okuda K, Wigzell H, Wahren B.

J Virol. 1997 Jul;71(7):5528-39.

5.

Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.

Calarota SA, Kjerrström A, Islam KB, Wahren B.

Hum Gene Ther. 2001 Sep 1;12(13):1623-37.

PMID:
11535166
6.

Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef.

Allard SD, Pletinckx K, Breckpot K, Heirman C, Bonehill A, Michiels A, van Baalen CA, Gruters RA, Osterhaus AD, Lacor P, Thielemans K, Aerts JL.

Vaccine. 2008 Jul 4;26(29-30):3735-41. doi: 10.1016/j.vaccine.2008.04.077. Epub 2008 May 20.

PMID:
18539368
7.

Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.

Harrer E, Bäuerle M, Ferstl B, Chaplin P, Petzold B, Mateo L, Handley A, Tzatzaris M, Vollmar J, Bergmann S, Rittmaier M, Eismann K, Müller S, Kalden JR, Spriewald B, Willbold D, Harrer T.

Antivir Ther. 2005;10(2):285-300.

PMID:
15865223
8.

HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.

Andrés C, Plana M, Guardo AC, Alvarez-Fernández C, Climent N, Gallart T, León A, Clotet B, Autran B, Chomont N, Gatell JM, Sánchez-Palomino S, García F.

J Virol. 2015 Sep;89(18):9189-99. doi: 10.1128/JVI.01062-15. Epub 2015 Jun 24.

9.

Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment.

Calarota SA, Leandersson AC, Bratt G, Hinkula J, Klinman DM, Weinhold KJ, Sandström E, Wahren B.

J Immunol. 1999 Aug 15;163(4):2330-8.

10.

Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.

Gudmundsdotter L, Wahren B, Haller BK, Boberg A, Edbäck U, Bernasconi D, Buttò S, Gaines H, Imami N, Gotch F, Lori F, Lisziewicz J, Sandström E, Hejdeman B.

Vaccine. 2011 Jul 26;29(33):5558-66. doi: 10.1016/j.vaccine.2011.01.064. Epub 2011 Feb 5.

PMID:
21300092
11.

Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Jacobson JM, Routy JP, Welles S, DeBenedette M, Tcherepanova I, Angel JB, Asmuth DM, Stein DK, Baril JG, McKellar M, Margolis DM, Trottier B, Wood K, Nicolette C.

J Acquir Immune Defic Syndr. 2016 May 1;72(1):31-8. doi: 10.1097/QAI.0000000000000926.

12.

MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.

Kutscher S, Allgayer S, Dembek CJ, Bogner JR, Protzer U, Goebel FD, Erfle V, Cosma A.

Gene Ther. 2010 Nov;17(11):1372-83. doi: 10.1038/gt.2010.90. Epub 2010 Jun 10.

PMID:
20535218
13.

Cytotoxic T-lymphocyte induction in asymptomatic HIV-1-infected patients immunized with Retrovector-transduced autologous fibroblasts expressing HIV-1IIIB Env/Rev proteins.

Ziegner UH, Peters G, Jolly DJ, Mento SJ, Galpin J, Prussak CE, Barber JR, Hartnett DE, Bohart C, Klump W, et al.

AIDS. 1995 Jan;9(1):43-50.

PMID:
7893440
14.

Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial.

Gandhi RT, Kwon DS, Macklin EA, Shopis JR, McLean AP, McBrine N, Flynn T, Peter L, Sbrolla A, Kaufmann DE, Porichis F, Walker BD, Bhardwaj N, Barouch DH, Kavanagh DG.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):246-53. doi: 10.1097/QAI.0000000000000852.

15.

Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals.

Reiss P, de Wolf F, Kuiken CL, de Ronde A, Dekker J, Boucher CA, Debouck C, Lange JM, Goudsmit J.

J Acquir Immune Defic Syndr. 1991;4(2):165-72.

PMID:
1898969
16.

A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.

García F, Climent N, Guardo AC, Gil C, León A, Autran B, Lifson JD, Martínez-Picado J, Dalmau J, Clotet B, Gatell JM, Plana M, Gallart T; DCV2/MANON07-ORVACS Study Group..

Sci Transl Med. 2013 Jan 2;5(166):166ra2. doi: 10.1126/scitranslmed.3004682.

18.

Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.

Ide F, Nakamura T, Tomizawa M, Kawana-Tachikawa A, Odawara T, Hosoya N, Iwamoto A.

J Med Virol. 2006 Jun;78(6):711-8.

PMID:
16628588
19.
20.

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals.

Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A, Brander C, Robbins GK, Mazzara GP, Goulder PJ, Walker BD; HIV Controller Study Collaboration..

Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1781-6.

Supplemental Content

Support Center